The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Pulmonary/Critical Care. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Mon, 08 Jun 2026 01:55:29 GMT 2026 NEJM Group en-us 1440 In a multicenter trial involving patients with acute hypoxemic respiratory failure, 28-day mortality with high-flow oxygen was not significantly different from that with standard oxygen. https://www.nejm.org/doi/full/10.1056/NEJMoa2516087?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516087 Jean-Pierre Frat, Jean-Pierre Quenot, Christophe Guitton, Rémi Coudroy, Arnaud Gacouin, Julio Badie, Alexandre Demoule, Damien Contou, Guillaume Carteaux, Stephan Ehrmann, Fabien Jarousseau, Nicholas Sedillot, Jean-Philippe Rigaud, Jean Reignier, François Beloncle, Anne-Florence Dureau, Alexis Ferré, Cédric Daubin, Anna Bourreau, Agathe Delbove, Gaël Pradel, Abdelhamid Fatah, Gwenhael Colin, Guillaume Deniel, Olivier Lamouret, Béatrice La Combe, Gwénaël Prat, Louis-Marie Galerneau, Gaël Bourdin, Gautier Julien, Anaïs Curtiaud, Mélanie Saint-Léger, Emanuele Turbil, Faustine Reynaud, Louis Chamblet, Stéphanie Ragot, Arnaud W. Thille, the SOHO Trial Group and the REVA Network* 2026-06-04 High-Flow or Standard Oxygen in Acute Hypoxemic Respiratory Failure Acute hypoxemic respiratory failure remains one of the most common conditions encountered in the intensive care unit (ICU).1 During the past decade, high-flow nasal oxygen has moved from physiological curiosity to frontline therapy.2 Early enthusiasm followed the publication of the results of the 2015 FLORALI trial, https://www.nejm.org/doi/full/10.1056/NEJMe2602037?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2602037 Ary Serpa Neto 2026-06-04 Rethinking High-Flow Oxygen in Acute Hypoxemic Respiratory Failure IgG4-related disease has emerged as one of the clearest human models for understanding the role of B-lineage cells in immune-mediated inflammation. Although glucocorticoids remain effective for inducing remission, relapse during tapering is common, cumulative toxic effects are substantial, and durable disease control remains difficult to achieve. Della-Torre et al.1 https://www.nejm.org/doi/full/10.1056/NEJMe2605617?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2605617 Thomas Dörner 2026-06-02 Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease In patients with pulmonary embolism, ultrasound-facilitated, catheter-directed fibrinolysis led to a lower risk of a composite of major adverse outcomes than anticoagulation alone. https://www.nejm.org/doi/full/10.1056/NEJMoa2516567?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516567 Kenneth Rosenfield, Frederikus A. Klok, Gregory Piazza, Andrew S.P. Sharp, Fionnuala Ní Áinle, Michael R. Jaff, Stefano Barco, Samuel Z. Goldhaber, Nils Kucher, Irene M. Lang, Irene Schmidtmann, Keith M. Sterling, Aleksander Araszkiewicz, Vishal Arora, Rafael Cires-Drouet, John Coghlan, Lukas Hobohm, Wulf D. Ito, Kurt Jacobson, Christoph Kaiser, Grzegorz Kopec, Kristin Marx, Samuel McElwee, Nicolas Meneveau, Peter Monteleone, Jose M. Montero-Cabezas, Christoph B. Olivier, John Park, Marek Roik, Rahul Sakhuja, Andi Tego, Markus Theurl, Gautam Visveswaran, Jan Albert Vos, Michael N. Young, Federico M. Asch, Stavros V. Konstantinides, the HI-PEITHO Investigators* 2026-05-28 Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism Bronchoscopy in a 77-year-old man with suspected lung cancer showed black patches on the bronchial mucosa. Biopsy revealed ciliated epithelium with subepithelial accumulation of macrophages containing black pigment. https://www.nejm.org/doi/full/10.1056/NEJMicm2516602?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2516602 Fredrik Eika, Torpiki Abdul Abdulhaq 2026-05-28 Bronchial Anthracosis Pulmonary embolism is the third leading cardiovascular cause of complications and death after myocardial infarction and stroke, with a rising incidence globally.1 The approach to management of acute pulmonary embolism as a condition to be treated nonsurgically with systemic heparin anticoagulation was established more than 60 years ago. https://www.nejm.org/doi/full/10.1056/NEJMe2603115?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603115 Alex C. Spyropoulos, Suresh Vedantham 2026-05-28 Advanced Therapy for Intermediate-Risk Pulmonary Embolism The story of the pulse oximeter demonstrates that sometimes consideration of race is critical to diagnosis and treatment — as came starkly into light during the Covid-19 pandemic. https://www.nejm.org/doi/full/10.1056/NEJMp2601977?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601977 2026-05-28 Intention to Treat — Season 2: The Race Equation: When Race Matters — ITT Episode 2.4 Among patients with idiopathic pulmonary fibrosis, inhaled treprostinil led to a smaller decline in forced vital capacity than placebo over 52 weeks. Cough and drug discontinuation were more common with treprostinil. https://www.nejm.org/doi/full/10.1056/NEJMoa2501488?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2501488 Steven D. Nathan, Peter Smith, Chunqin Deng, Christopher S. King, Maria De Salvo, S. Samuel Weigt, Sahil Pandya, Debabrata Bandyopadhyay, Joseph A. Lasky, Rachana Krishna, Nathan Hambly, Murali Ramaswamy, Jad Kebbe, Neil Ettinger, Jamie Gao, Youlan Rao, Natalie Breytenbach, Leigh Peterson, Heidi Bell, Juergen Behr, Vincent Cottin, Kevin R. Flaherty, the TETON-1 Trial Investigators* 2026-05-18 Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis Azithromycin did not lead to a greater reduction in symptom severity than placebo among preschool children presenting to the emergency department with wheezing, regardless of whether they tested positive for pathogenic bacteria. https://www.nejm.org/doi/full/10.1056/NEJMoa2516505?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516505 Kurt R. Denninghoff, T. Charles Casper, Joseph J. Zorc, Richard M. Ruddy, Sarah Satola, Wendi-Jo Wendt, Claudia R. Morris, Melissa M. Tavarez, Matthew J. Lipshaw, Maria Y. Kwok, Jo-Ann O. Nesiama, Kyle A. Nelson, Michael Webb, Fernando D. Martinez, the PECARN AZ-SWED Trial Study Group* 2026-05-18 Azithromycin for Preschoolers with Wheezing in the Emergency Department Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. https://www.nejm.org/doi/full/10.1056/NEJMoa2602167?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602167 Jason L. Sperry, Francis X. Guyette, Bryan A. Cotton, James F. Luther, Richard B. Utarnachitt, Matthew E. Kutcher, Brian J. Daley, Allan B. Peetz, Mayur B. Patel, Michael D. Goodman, Jeffrey A. Claridge, Nimitt Patel, Brian G. Harbrecht, Zain G. Hashmi, Ryan Zarychanski, Matthew D. Neal, Mark H. Yazer, Christian Martin-Gill, Laura E. Vincent, Ashley M. Harner, David E. Meyer, Andrew J. Latimer, Bryce R. Robinson, Catherine L. McKnight, William R. Hinckley, Keith R. Miller, Jan O. Jansen, Douglas Martin, Erin E. Fox, Bedda L. Rosario-Rivera, Stephen R. Wisniewski, the TOWAR Study Group* 2026-05-18 Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage Among patients with stroke due to medium-vessel occlusion, thrombectomy led to functional independence at 90 days (in 58.6% of patients, vs. 46.6% with medical management) but also to a higher risk of intracranial hemorrhage. https://www.nejm.org/doi/full/10.1056/NEJMoa2514120?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2514120 Wei Hu, Xiaozhong Jing, Zhongjun Chen, Jin Zheng, Tingyu Yi, Tuanyuan Zheng, Zhide Li, Junzhong Liu, Tao Cui, Jianshang Wen, Ganghua Feng, Cunfeng Song, Lei Yang, Shunfu Jiang, Lin Tong, Changchun Jiang, Zhongfan Ruan, ˒Peiyang Zhou, Shouchun Wang, Tao Wang, Zhiming Zhou, Youquan Ren, Tao Qiu, Chong Zheng, Hao Wang, Yong Liu, Yun Luo, Jing Wang, Zhengfei Ma, Bin Mei, Yong Liang, Yuyou Zhu, Rui Li, Jun Sun, Li Wang, Chao Zhang, Tianlong Liu, Jianlong Song, Chunrong Tao, Anmo Wang, Jinjing Wang, Pengfei Xu, Xiaofan Guo, Liqi Shu, Adnan I. Qureshi, Thanh N. Nguyen, Mohamad AbdalKader, Jeffrey L. Saver, Wenhuo Chen, Raul G. Nogueira 2026-05-14 Endovascular Treatment of Medium-Vessel-Occlusion Strokes In a trial of brepocitinib in adults with dermatomyositis, the 30-mg dose (but not the 15-mg dose) led to greater improvement on a composite myositis index at 52 weeks than placebo. Serious infections were more frequent with the 30-mg dose. https://www.nejm.org/doi/full/10.1056/NEJMoa2503531?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2503531 Ruth Ann Vleugels, Julie J. Paik, Iazsmin Bauer Ventura, Aaron R. Mangold, Prateek C. Gandiga, Anna Haemel, Hector Chinoy, Yessar M. Hussain, Kumaraswamy Sivakumar, Zoltan Griger, Eun Bong Lee, Francisca Bozan, Chung-Yuan Hsu, Alisa Femia, Mazen M. Dimachkie, Michelle S. Min, Tahseen Mozaffar, Christina Charles-Schoeman, David R. Fernandez, Oluwakemi Onajin, Raquel Campanilho-Marques, Galina Marder, Floranne Ernste, Elena Schiopu, Jason Sluzevich, David Pearson, Stephen Lindsey, Michael Luggen, Michael R. Bubb, Erin Boh, Rashmi Maganti, Latisha Heinlen, Katharina S. Shaw, Matthew D. Cascino, Paul N. Mudd Jr., Jiri Vencovsky, Anthony P. Fernandez, David Fiorentino, Lisa Christopher-Stine, Victoria P. Werth, Rohit Aggarwal, the VALOR Investigators* 2026-05-14 A Phase 3 Trial of Brepocitinib in Dermatomyositis A 55-year-old man presented with cough, chest pain, and worsening dyspnea after being trapped in a burning house for 10 minutes. Bronchoscopy revealed carbonaceous deposits that extended along the airway (shown in a video). https://www.nejm.org/doi/full/10.1056/NEJMicm2517900?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2517900 Juan Huang, Cheng Yang 2026-05-14 Inhalation Injury from House Fire Smoke Dermatomyositis is a subgroup of idiopathic inflammatory myopathies — systemic autoimmune disorders that are typically characterized by the involvement of multiple organs, including muscle, skin, joints, lungs, gastrointestinal tract, and heart — all conditions with high morbidity and mortality.1 Treatment of myositis is based on off-label use of... https://www.nejm.org/doi/full/10.1056/NEJMe2604009?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2604009 Ingrid E. Lundberg 2026-05-14 A Phase 3 Trial of Brepocitinib in Dermatomyositis One way to classify acute ischemic stroke is by the anatomy of vessel occlusion. Initial randomized trials of endovascular thrombectomy focused on large-vessel occlusions.1-5 These proximal occlusions of the intracranial carotid artery or the stem of the middle cerebral artery (MCA) represent the most severe form of anterior... https://www.nejm.org/doi/full/10.1056/NEJMe2601852?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2601852 Johanna M. Ospel, Michael D. Hill 2026-05-14 Endovascular Therapy for Medium-Vessel Occlusion Stroke — Narrowing the Target Population The history of race-based correction of lung-capacity measures can be traced to a pre–Civil War belief among slave owners that slaves had naturally inferior lung capacity. Despite work to show that race-corrected spirometers mask lung-disease severity in Black patients, the majority of U.S. hospitals still use them. https://www.nejm.org/doi/full/10.1056/NEJMp2601975?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601975 2026-05-14 Intention to Treat — Season 2: The Race Equation: How Did Race Get Into Lung Testing? — ITT Episode 2.2 Rapid, affordable, and easy-to-use diagnostic testing for tuberculosis is needed. In a multinational study, the accuracy of a tuberculosis diagnostic deployable to peripheral health care centers was assessed. https://www.nejm.org/doi/full/10.1056/NEJMoa2509761?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2509761 Seda Yerlikaya, Masuzyo Chirwa, Bukola Ajide, Maria del Mar Castro, Huy Ha, Midori Kato-Maeda, Esther Kisakye, Danaida Marcelo, Tessa Mochizuki, Loren Rockman, Amy Steadman, Balamugesh Thangakunam, John Samson Bimba, Devasahayam J. Christopher, Monde Muyoyeta, Ha Phan, Grant Theron, Charles Yu, Kristin Kremer, Patrick P.J. Phillips, Payam Nahid, Claudia M. Denkinger, Adithya Cattamanchi, Alfred Andama, the R2D2 TB Network and SMART4TB Consortia* 2026-04-30 Pulmonary Tuberculosis Detection with MiniDock MTB Using Swab Samples In a phase 1 trial of first-line zongertinib for HER2-mutated non–small-cell lung cancer, an objective response occurred in 76% of patients, with a median progression-free survival of 14.4 months. https://www.nejm.org/doi/full/10.1056/NEJMoa2516969?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516969 John V. Heymach, Noboru Yamamoto, Nicolas Girard, Gerrina Ruiter, Egbert F. Smit, David Planchard, Ernest Nadal, Yi-Long Wu, Jon Zugazagoitia, Hai-Yan Tu, Christina S. Baik, Kiyotaka Yoh, Ross A. Soo, Yanqiu Zhao, Joshua K. Sabari, Martin Wermke, Matthias Scheffler, Myung-Ju Ahn, Kristie Fernamberg, Lukas Schroeter, Behbood Sadrolhefazi, Claus Thamer, Sabina Eigenbrod-Giese, Sanjay Popat, the Beamion LUNG-1 Investigators* 2026-04-30 First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer The discovery that many lung cancers are driven by a single dominant constitutively activated “driver” oncogene represented a quantum leap in the therapy of lung cancer. Potent small molecules were developed that could turn off these genes, with dramatic clinical therapeutic efficacy. Before their discovery, cancer therapeutics were identified by... https://www.nejm.org/doi/full/10.1056/NEJMe2603357?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603357 David P. Carbone 2026-04-30 EGFR’s Poor Sibling Among survivors of intracerebral hemorrhage, a single pill with three low-dose antihypertensive agents added to standard care was associated with a lower incidence of stroke and major cardiovascular events than placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2515043?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2515043 The Trident Research Group, Craig S. Anderson, Clara K. Chow, H. Asita de Silva, Bimsara Senanayake, Kolawole Wahab, Rustam Al-Shahi Salman, Catharina J.M. Klijn, Sheila Ouriques Martins, Natalie Espinosa, Lauren Kuhles, Laurent Billot, Hisatomi Arima, Cheryl Carcel, Xia Wang, Qiang Li, Sana Shan, Mathangi Shanthakumar, Huy Thang Nguyen, Dilum Palliyaguruge, Janaka Peiris, Udaya K. Ranawaka, Senaka Bandusena, Thambipillai Rajendiran, Darshana Wijegunasinghe, Harsha Gunasekera, Indunil Wijeweera, Athula Dissanayake, Ajantha Keshavaraj, Reginald O. Obiako, Rufus Akinyemi, Luiz Nasi, Rodrigo Bazan, Carla Heloisa Cabral Moro, Mariana Battaglini, Viviane Zétola, Wan Chung Law, Yuen Kang Chia, Dennis Cordato, Rohan Grimley, Anuradha Dahanayaka, Sonali Liyanagamage, Nilukshi Fernando, Nihara Abdul Rasheed, Nodar Kakabadze, Maia Beridze, Mythily Aravinthan, Vithoosan Sahathevan, Devasmitha Wijesundara, Pramith Ruwanpathirana, Wan Asyraf Wan Zaidi, Tinatin Kherkheulidze, Urs Fischer, Ana Cláudia de Souza, Tsong-Hai Lee, Christopher Chen, Octavio Pontes-Neto, Thompson Robinson, Jiguang Wang, Sharon L. Naismith, Michael Barnett, Carlos Delfino, Shoujiang You, Feifeng Liu, Candice Delcourt, Tom J. Moullaali, Tim Wilkinson, Neil Watson, Karla Santo, Qiao Han, Mariana Almudi Souza, Wilmar M.T. Jolink, Anderson Berni Cristofari, Zien Zhou, Floris H. Schreuder, Richard I. Lindley, Manuela Armenis, Mark Woodward, Ruth Freed, Lili Song, John Chalmers, Anthony Rodgers 2026-04-23 Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage